Comparison

Abaloparatide (TFA)

Item no. CS-0104482-5mg
Manufacturer ChemScene
Amount 5mg
Category
Type Molecules
Specific against other
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Available
Alternative Names
BA 058 (TFA); BIM 44058 (TFA)
Purity
>98%
MWt
4074.61
Formula
C176H301N56F3O51
Solubility
H2O : >= 50 mg/mL (12.27 mM)
Clinical Information
Launched
Pathway
Others
Target
Thyroid Hormone Receptor
Biological Activity
Abaloparatide TFA (BA 058 TFA) is a parathyroid hormone receptor 1 (PTHR1) analogue selected to be a potent and selective activator of the PTHR1 signaling pathway. Abaloparatide TFA enhances Gs/cAMP signaling (EC50 of 0.3 nM) and beta-arrestin recruitment (EC50 of 0.9 nM) in MC3T3-E1 osteoblast cells[1][2]. IC50 & Target: Parathyroid hormone receptor 1 (PTHR1)[1] In Vitro: MC3T3-E1 osteoblast cells are treated with 0.01-100 nM of Abaloparatide for 40 min at 37 C in the presence of 0.5 mM IBMX. The results reveals that exposure of cells to Abaloparatide caused a robust elevation of intracellular cAMP levels. Abaloparatide treatment results in a 2.3-fold decrease in EC50 value for cAMP formation compared to teriparatide (EC50s of 0.3 nM and 0.7 nM, respectively)[1].
A dose-dependent stimulation of beta-arrestin/PTHR1 interaction is demonstrated by abaloparatide. Consistently, the calculates the EC50 value for abaloparatide is 1.6-fold lower than that of teriparatide (EC50s of 0.9 nM and 1.5 nM, respectively)[1].
Abaloparatide efficiently induces a dose-dependent stimulation of PTHR1 internalization with a dose as low as 0.1 nM and reaches maximum stimulation at 100 nM concentration. The EC50 value of 0.8 nM for Abaloparatide[1]. In Vivo: Abaloparatide (1-25 ug/kg; subcutaneous injection; daily; for 12 months; female Sprague-Dawley rats) treatment increases biochemical bone formation markers, histomorphometric indices of bone formation on trabecular, endocortical, and periosteal surfaces. Abaloparatide induces substantial increases in trabecular bone volume and density and improvements in trabecular microarchitecture. Abaloparatide stimulates periosteal expansion and endocortical bone apposition at the tibial diaphysis, leading to marked increases in cortical bone volume and density. Whole-body bone mineral density (BMD) is increasing 25% after 12 months of abaloparatide (25?ug/kg) in osteopenic ovariectomized (OVX) rats[2].
Research Area
Metabolic Disease; Endocrinology

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 5mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close